EXAS (Exact Sciences) 6-1 Month Momentum % : 18.67% (As of Dec. 15, 2024)

View and export this data going back to 2001. Start your Free Trial

What is Exact Sciences 6-1 Month Momentum %?

6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2024-12-15), Exact Sciences's 6-1 Month Momentum % is 18.67%.

The industry rank for Exact Sciences's 6-1 Month Momentum % or its related term are showing as below:

EXAS's 6-1 Month Momentum % is ranked better than
72.73% of 231 companies
in the Medical Diagnostics & Research industry
Industry Median: -1.66 vs EXAS: 18.67

Competitive Comparison of Exact Sciences's 6-1 Month Momentum %

For the Diagnostics & Research subindustry, Exact Sciences's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Exact Sciences's 6-1 Month Momentum % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Exact Sciences's 6-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Exact Sciences's 6-1 Month Momentum % falls into.

Exact Sciences (NAS:EXAS) 6-1 Month Momentum % Calculation

6-1 Month Momentum % is calculated as following:

6-1 Month Momentum %

( Price 1-month ago

Price 6-month ago

- 1 )

100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Exact Sciences (NAS:EXAS) 6-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Exact Sciences 6-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Exact Sciences's 6-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.

Exact Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Exact Sciences Corp (NAS:EXAS) » Definitions » 6-1 Month Momentum %

Comparable Companies

CRL QGEN MEDP RDNT RVTY GH SHC NEOG VCYT TWST TMO DHR XSWX:LONN A IQV IDXX MTD ILMN WAT NTRA

Traded in Other Exchanges

EXK:Germany EXK:Germany

Address

5505 Endeavor Lane, Madison, WI, USA, 53719

Website

https://www.exactsciences.com

Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a precancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.

Executives

Kevin T Conroy	director, officer: Vice President	5505 ENDEAVOR LANE, MADISON WI 53719
Brian Baranick	officer: Gen. Mgr., Precision Oncology	441 CHARMANY DRIVE, MADISON WI 53719
Jacob A Orville	officer: General Manager, New Ventures	5505 ENDEAVOR LANE, MADISON WI 53719
James Herriott	officer: General Counsel	5505 ENDEAVOR LANE, MADISON WI 53719
Sarah Condella	officer: SVP, Human Resources	441 CHARMANY DRIVE, MADISON WI 53719
D Scott Coward	officer: SVP and General Counsel	441 CHARMANY DRIVE, MADISON WI 53719
Jeffrey Thomas Elliott	officer: Chief Financial Officer	5505 ENDEAVOR LANE, MADISON WI 53719
Everett Cunningham	officer: Chief Commercial Officer	C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094
Daniel J Levangie	director	85 SWANSON ROAD, BOXBOROUGH MA 01719
James Edward Doyle	director	5505 ENDEAVOR LANE, MADISON WI 53719
Timothy J Scannell	director	2825 AIRVIEW BOULEVARD, KALAMAZOO MI 49002
Katherine S Zanotti	director	431 E 9TH STREET, HINSDALE IL 60521
Paul J Clancy	director	C/O BIOGEN IDEC INC., 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
Graham Peter Lidgard	officer: SVP, Chief Scientific Officer	5505 ENDEAVOR LANE, MADISON WI 53719
Michael S Wyzga	director	RADIUS HEALTH, INC., 201 BROADWAY, 6TH FLOOR, CAMBRIDGE MA 02139